Rheumatoid arthritis is a serious disease. Unlike osteoarthritis, which results from wear and tear on joints, rheumatoid arthritis is an autoimmune condition where the immune system attacks the body’s own tissues. It can destroy joints permanently, affect organs like the heart and lungs, and shorten lifespan. The good news: modern treatments have dramatically improved outcomes, with more than half of patients on current therapies achieving remission.
How RA Damages Your Joints
The core problem in rheumatoid arthritis is chronic inflammation of the synovial membrane, the thin lining inside your joints. Over time, this membrane thickens and grows into what’s called a pannus, an aggressive layer of tissue that invades the cartilage and bone at the joint margins. Specialized bone-dissolving cells accumulate at the border between this inflamed tissue and the bone, creating pits that eventually become full erosions.
What makes this damage particularly serious is that it’s a one-way street. The same inflammatory signals that accelerate bone destruction also block the cells responsible for bone repair. Your body can’t rebuild what the disease tears down. This is why early treatment matters so much: there’s a window of roughly 3 to 6 months after symptoms begin during which starting therapy can prevent irreversible joint damage. Patients treated within this window consistently have better long-term outcomes than those who wait.
Effects Beyond the Joints
About 40% of people with RA develop problems outside the joints at some point during their disease. The inflammation driving RA is systemic, meaning it circulates through the bloodstream and can settle in organs throughout the body.
The lungs are one of the most commonly affected organs. Pleural involvement (inflammation of the lining around the lungs) shows up in autopsy studies in roughly half of RA patients, though only about 10% ever develop noticeable symptoms from it. A more dangerous complication is interstitial lung disease, which involves scarring of the lung tissue itself. Clinically significant lung disease develops in close to 10% of people with RA and is associated with dying an average of 2.5 to 3.5 years earlier than RA patients without lung involvement.
The heart faces similar risks. Inflammation of the sac surrounding the heart appears in about half of RA patients at autopsy, though symptomatic cases are far less common. More broadly, people with RA have 1.5 to 2 times the risk of developing coronary artery disease compared to the general population, and the rate of heart attacks is roughly double. This elevated cardiovascular risk is driven by the chronic inflammation itself, which accelerates plaque buildup in arteries.
Dry eyes affect at least 10% of RA patients, and anemia is common. Rheumatoid nodules, firm lumps under the skin near affected joints, develop in up to 30% of patients.
Impact on Work and Daily Life
RA’s effects on daily functioning are significant and cumulative. Among people with 1 to 3 years of disease, 23% have already stopped working prematurely. By the 10-year mark, that number rises to 35%. For those living with RA for 25 years or more, over half have experienced premature work cessation, with 42% attributing it directly to their arthritis.
Joint damage in the hands, wrists, and feet can make routine tasks like opening jars, typing, or walking painful and eventually difficult. Fatigue is another underappreciated feature of the disease. The persistent systemic inflammation creates a deep, ongoing tiredness that sleep doesn’t fully resolve.
Does RA Shorten Your Life?
It can, though the effect with modern treatment is smaller than many people fear. In recent long-term studies of patients treated with current strategies, life expectancy was shortened by approximately one year on average. That’s a meaningful difference, but far less dramatic than the 5- to 10-year reductions seen in older studies from decades when fewer effective treatments existed.
The leading causes of death in RA patients are cancer (30 to 39% of deaths) and cardiovascular disease (21 to 24%). Infection accounts for a smaller but notable share. RA itself increases infection risk because the immune system is both dysfunctional from the disease and further suppressed by many of the medications used to treat it. Patients on biologic therapies have roughly 30 to 50% higher rates of serious infections compared to those on conventional medications. Lung disease, diabetes, and accumulating other health conditions all compound this risk.
How Treatable Is RA Today?
This is where the picture has changed most in recent decades. With biologic therapies and other modern medications, a meta-analysis of 21 studies found that about 53% of patients achieved complete remission within 6 to 12 months of treatment. Some individual studies reported remission rates as high as 67%. Remission in this context means the disease is quiet enough that it’s no longer causing active joint damage or significant symptoms.
Even patients who don’t reach full remission can often achieve low disease activity, a state where symptoms are manageable and joint destruction slows considerably. The key factor is starting treatment early and adjusting it aggressively until the disease is controlled. Patients treated within that initial 3- to 6-month window consistently do better over the long term than those whose treatment is delayed.
RA remains a lifelong condition that requires ongoing medication and monitoring. Stopping treatment, even in remission, often leads to flares. But the trajectory of the disease today looks fundamentally different from what it was 30 years ago, when progressive joint deformity and disability were common outcomes. For most people diagnosed now and treated promptly, severe disability is no longer inevitable.